LILRB4 and acute myeloid leukemia: Humanized LILRB4 antibody h128-3 has been shown promote LILRB4 internalization and subsequent degradation through multiple mechanisms which contribute to increased functional antagonism of the receptor, however may also contribute to target antigen loss in the AML cell [76].